Business Development
Acacia Pharma aims to out-license its internally derived products outside selected European countries once the Company has added sufficient value through clinical development.
In addition, Acacia Pharma is seeking to in-license or acquire clinical-stage product candidates for supportive care to complement its current development pipeline. If you are interested in discussing the Company’s out-licensing opportunities, or have products or product developments you are seeking to divest, please contact Dr Julian Gilbert (+44(0)1223 875130).